Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03644186). This is a study registration, not published results. Lead sponsor: ETOP IBCSG Partners Foundation. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 147 participants (ACTUAL). Conditions: Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer. Interventions: DRUG: Paclitaxel; DRUG: Trastuzumab; DRUG: Pertuzumab; DRUG: Palbociclib; DRUG: Letrozole; DRUG: Trastuzumab; DRUG: Pertuzumab. Primary outcome measures: Pathological Complete Response (pCR) , Assessed within 30 days of the time of breast surgery after completion of a treatment period of up to 16 weeks; up to 21 weeks. If the patient does not undergo surgery, assessment will occur within 30 days after all treatment is stopped; up to 30 weeks.. Brief summary: This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.